Novo Nordisk’s GLP-1 pill gets EU approval for cardiovascular benefits
Novo Nordisk rose in early trading after it announced that European regulators approved its diabetes pill to be marketed for cardiovascular benefits as well.
Rybelsus — a pill version of semaglutide, the active ingredient in Ozempic and Wegovy — will now list cardiovascular benefits on its label in the European Union. In the US, the Food and Drug Administration is expected to decide on adding the cardiovascular indication for Rybelsus later this year.
Wegovy, Novo’s blockbuster weight-loss shot, is approved to treat cardiovascular conditions in the US and EU. Expanding the conditions Novo’s drugs can be prescribed for could help the Danish pharmaceutical giant spark growth as it faces pressure from Eli Lilly’s competitor drugs.